Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Essential Hypertension Clinical Trial

Official title:

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled, Factorial Study to Evaluate the Efficacy and Safety of 8-week Treatment With Valsartan (40 and 80 mg) and Amlodipine (2.5 and 5 mg) Combined and Alone in Essential Hypertensive Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00425373
• Other study ID #: CVAA489A1301
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: January 22, 2007
• Last updated: April 20, 2011
• Start date: November 2006
• Est. completion date: March 2008

Study information

• Verified date: April 2011
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: Japan: Ministry of Health, Labor and Welfare
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure. The study will investigate the dose response relationship for the combinations, monotherapies, and placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1474
• Est. completion date: March 2008
• Est. primary completion date: March 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 80 Years

Eligibility

Inclusion criteria

• Patients with essential hypertension measured by electronic hemodynamometer. - - Patients must satisfy the following criteria.

1. MSDBP <110 mmHg and MSSBP <180 mmHg at Visit 1

2. MSDBP = 90 mmHg and < 110 mmHg and MSSBP < 180 mmHg at Visit 2

3. MSDBP = 95 mmHg and < 110 mmHg and MSSBP < 180 mmHg at Visit 3

4. The absolute difference in MSDBP between Visit 2 and 3 is = 10 mmHg

• Male or female outpatients.

• Aged => 20 and =< 80 years (at the time of signing informed consent).

• Patients who have written informed consent to participate in this study.

Exclusion criteria

• Pregnant women, nursing (lactating) mothers, women suspected of being pregnant, or women who wish to be pregnant during the study, women of child-bearing potential.

• Patients with secondary hypertension or suspected of having secondary hypertension.

• Patients with a history of malignant hypertension.

• Patients with an inability to completely discontinue all prior antihypertensive medications safely for a period of 12 weeks as required by the protocol.

• Patients with or with a history of any of the following diseases or signs: Cardiac disease, renal disease, cerebrovascular disorder

• Patients with a clinically significant allergy (asthma on pharmacotherapy, multi-drug allergy, or drug-induced or food-induced anaphylactic reactions).

• Patients hypersensitive to AII receptor antagonists, calcium channel blockers or dihydropyridine derivatives.

• Known moderate or malignant retinopathy.

• Patients with or with a history of pancreatitis. Patients with pancreatic injury, or evidence of impaired pancreatic function/injury within 12 months of Visit 1.

• Patients with any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.

• Patients with volume depletion based on the investigator's or subinvestigator's clinical judgment using vital signs, skin turgor, moistness of mucous membrane and laboratory values.

• Patients who are found to have low Na and K (Na <130 mEq/L, K <3.3mEq/L) or high in these parameters (Na = 152 mEq/L, K = 5.2 mEq/L) by laboratory tests at Visit 1.

• Patients with type I diabetes mellitus on treatment with insulin, or patients with type II diabetes with poor glucose control defined as a glycosylated hemoglobin (HbA1c) > 8.0% at Visit 1.

• Patients with or with a history of malignant tumors including leukemia and lymphoma, treated or untreated, within the past 5 years of Visit 1 whether or not there is evidence of local recurrence or metastases (except for localized basal cell carcinoma of the skin).

• Patients with any severe, life-threatening disease within the past 5 years. Patients with a history of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

• Any surgical or medical condition, which in the opinion of the investigator or subinvestigator, place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirement of the study or completing the trial period.

• Patients who have with or with a history of drug or alcohol abuse within the last 2 years of Visit 1. Patients who have received other investigational product within 12 weeks of Visit 1.

• Any chronic inflammatory condition needing chronic anti-inflammatory drug therapy.

• Persons directly involved in the execution of this study.

• Patients who are considered unlikely to comply with the requirements specified in the protocol by the investigator or subinvestigator.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Essential Hypertension
• Hypertension

Intervention

Drug:
• Valsartan + amlodipine 40/2.5 mg
Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
• Valsartan + amlodipine 40/5 mg
Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
• Valsartan + amlodipine 80/2.5 mg
Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
• Valsartan + amlodipine 80/5 mg
Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
• Valsartan 40 mg
Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
• Valsartan 80 mg
Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
• Amlodipine 2.5 mg
Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
• Amlodipine 5 mg
Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
• Placebo
4 tablet and 2 capsule placebos taken once daily

Locations

Country	Name	City	State
Japan	Novartis Pharmaceuticals	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)	At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.	Baseline to end of study (Week 8)	No
Secondary	Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)	At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.	Baseline to end of study (Week 8)	No
Secondary	Percentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)	At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.	Baseline to end of study (Week 8)	No
Secondary	Percentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8)	At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.	Baseline to end of study (Week 8)	No
Secondary	Percentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8)	At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.	Baseline to end of study (Week 8)	No